A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Active, not recruiting · Phase 2 · NCT04245839
Conditions: Lymphoma, Non-Hodgkin
At a glance
- Research payments reported, 2025
- $2.6M
- U.S. investigators named
- 19
- Sites paid
- 19
- Planned or actual enrollment
- 276
About the trial
- Sponsor
- Celgene
- Tested
- Fludarabine (drug), Cyclophosphamide (drug), JCAR017 (drug)
- Dates
- Started 2020-07-14; completion 2031-09-30
- Results posted
- Not yet
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: * Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; * Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with fo…
From ClinicalTrials.gov, last updated 2025-11-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celgene Corporation reported $2.6M in research payments for this study in 2025 (19 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sven De Vos, MD Hematology & Oncology · Los Angeles, CA
- Manali K. Kamdar, MD Hematology & Oncology · Aurora, CO
- Iris Isufi, M.D. Hematology & Oncology · New Haven, CT
- Reem Karmali, MD Hematology & Oncology · Chicago, IL
- Bassam I. Mattar, MD Hematology & Oncology · Wichita, KS
- Jeremy S. Abramson, MD Medical Oncology · Boston, MA
- Aaron P. Rapoport, M.D. Hematology · Baltimore, MD
- Dipenkumar K. Modi, M.D. Internal Medicine · Detroit, MI
- Alan P. Zausner Skarbnik, MD Hematology · Charlotte, NC
- Mohamad A. Cherry, MD Hematology & Oncology · Morristown, NJ
- Maria L. Palomba, MD Hematology & Oncology · New York, NY
- Brian T. Hill, M.D., PH.D. Hematology & Oncology · Cleveland, OH
- Stacy K. Lewis, MD Medical Oncology · Portland, OR
- Stephen J. Schuster, MD Hematology & Oncology · Philadelphia, PA
- Houston E. Holmes III, M.D. Hematology & Oncology · Dallas, TX
- Loretta J. Nastoupil, M.D. Hematology & Oncology · Houston, TX
- Sai Ravi Kiran Pingali, MD Hematology & Oncology · Houston, TX
- Indumathy Varadarajan, MD Hematology · Charlottesville, VA
- Alexandre Vinaud Hirayama, M.D. Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cleveland Clinic, OH $528,150
- Memorial Sloan-Kettering Cancer Center - Cancer $428,871
- Dana-Farber Cancer Institute $262,513
- Regents of the University of Colorado $239,688
- Karmanos Cancer Center, MI $228,084
- Novant Health Huntersville Medical Center, NC $184,689
- University of Washington Medical Ctr, WA $142,155
- Northwestern University School of Medicine $111,451
- University of Virginia Medical Center, VA $97,275
- Hospital of Univ of Pennsylvania, PA $75,756
- Baylor Research Institute $64,533
- University of Maryland, Baltimore $62,657
- Providence Portland Medical Center, OR $59,493
- Ut MD Anderson Cancer Center $49,513
- Morristown Medical Center, NJ $39,860
- Houston Methodist Research Institute $25,850
- Lee Daeyeol Mms $13,202
- Cancer Center of Kansas $12,410
- Ronald Reagan UCLA Medical Center, CA $11,654
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.